A significant number of individuals who start smoking cannabis develop a cannabis use disorder (CUD) and seek treatment on their own initiative, yet only a small percentage achieves sustained abstinence. Efficacious treatments for CUD are critically needed. We have developed placebo-controlled, laboratory procedures that target the effects of medications on discrete features of problematic cannabis use: positive subjective effects (cannabis 'liking'), reinforcement (cannabis self-administration under non-abstinent conditions), withdrawal (mood, sleep, food intake) and relapse (cannabis self-administration after a period of abstinence). Project 1 of this P50 Center refines and formalizes this model by developing a Decision Algorithm, utilizing a priori criteria to systematically define whether potential medications qualify to be tested in a clinical study, need to be tested further in the laboratory, or are rejected: (1) Positive signal: If a medication significantly decreases cannabis withdrawal and/or positive subjective effects and decreases cannabis self-administration, the medication will be tested in the clinic (Project 2), (2) Promising signal: If a medication decreases cannabis'positive subjective effects or cannabis withdrawal but does not alter cannabis self-administration, we will combine the medication with a cannabinoid agonist (nabilone) or opioid antagonist (sustained-release naltrexone: SR-NTX), respectively, and test the medication combination in the laboratory, (3) Negative signal: If a single or combination medication therapy produces no change in positive subjective effects, withdrawal, relapse or self- administration, we will halt further testing with this medication. The following medications with distinct neurobiological mechanisms will be tested: (1) Lorcaserin: 5HT2c agonists reduce behaviors reinforced by a range of drugs. Hypothesis: Lorcaserin will attenuate cannabis'positive subjective effects and facilitate abstinence initiation, i.e., reduce cannabis self-administration under non-abstinent conditions. (2) Cannabidiol (CBD): This cannabinoid has a complex neurobiology including inhibition of fatty acid amide hydrolase. Hypothesis: CBD will reduce cannabis withdrawal and relapse, (3) Doxazosin: ?1adrenergic antagonists dampen noradrenergic activity, which can result in reduced cannabis self-administration. Hypothesis: Doxazosin will attenuate cannabis'positive subjective effects and facilitate abstinence initiation, (4) Zonisamide: anticonvulsants that facilitate GABAergic while reducing glutamatergic neurotransmission reduce alcohol, cocaine and methamphetamine use in the clinic. Hypothesis: Zonisamide will attenuate cannabis' positive subjective effects and facilitate abstinence initiation. This proposal introduces a novel drug discovery algorithm to systematically screen medications for CUD, only advancing the mono- or combination therapies with the greatest likelihood of success in Project 2. Given the unique combination of laboratory and clinical expertise available in this Center, the outcome of Project 1 is predicted to both advance the field scientifically and address an unmet public health need: improving the treatment of CUD.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York State Psychiatric Institute
New York
United States
Zip Code
Haney, Margaret; Cooper, Ziva D; Bedi, Gillinder et al. (2018) Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Addict Biol :
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Jones, Jermaine D; Luba, Rachel R; Vogelman, Jonathan L et al. (2016) Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. Am J Addict 25:41-8
Jones, Jermaine D; Comer, Sandra D (2015) A review of pharmacogenetic studies of substance-related disorders. Drug Alcohol Depend 152:1-14